Citadel Advisors
NVOS

Citadel Advisors’s Novo Integrated Sciences, Inc. Common Stock NVOS Stock Holding History

Citadel Advisors’s Portfolio NVOS Stock Details NVOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-116,659
Closed -$95.8K – 15866
2023
Q4 		$95.8K Buy
+116,659
New +$237K ﹤0.01% 10987
2022
Q4 		– Sell
-2,338
Closed -$25K – 15694
2022
Q3 		$25K Buy
+2,338
New +$38K ﹤0.01% 11990
2021
Q3 		– Sell
-1,179
Closed -$30K – 14939
2021
Q2 		$30K Buy
+1,179
New +$29.4K ﹤0.01% 13482

Other funds holding NVOS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Citadel Advisors's NVOS Position: Q1 2024 in Review

Citadel Advisors sold out of Novo Integrated Sciences, Inc. Common Stock (NVOS) in Q1 2024, closing a stake of 116,659 shares — an estimated $95.8K sold.

Citadel Advisors first reported a position in NVOS in Q2 2021 and held it in 3 quarters. The position peaked at $95.8K in Q4 2023. 14 funds tracked by Wall St. Rank hold NVOS as of Q1 2024.

  • Citadel Advisors reported no remaining Novo Integrated Sciences, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Citadel Advisors sold 116,659 Novo Integrated Sciences, Inc. Common Stock shares in Q1 2024, an estimated $95.8K.
  • Citadel Advisors first reported a position in Novo Integrated Sciences, Inc. Common Stock in Q2 2021 and held it in 3 quarters.
  • Citadel Advisors's Novo Integrated Sciences, Inc. Common Stock position peaked at $95.8K in Q4 2023.
  • 14 funds tracked by Wall St. Rank held Novo Integrated Sciences, Inc. Common Stock as of Q1 2024.

Based on Citadel Advisors's 13F filing for Q1 2024, filed 15 May 2024.